UFD1L, a developmentally expressed ubiquitination gene, is deleted in CATCH 22 syndrome

Antonio Pizzuti, Giuseppe Novelli, Antonia Ratti, Francesca Amati, Aldo Mari, Giuseppe Calabrese, Silvia Nicolis, Vincenzo Silani, Bruno Marino, Guglielmo Scarlato, Sergio Ottolenghi, Bruno Dallapiccola

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

The CATCH 22 acronym outlines the main clinical features of 22q11.2 deletions (cardiac defects, abnormal facies, thymic hypoplasia; cleft palate and hypocalcemia), usually found in DiGeorge (DGS) and velo-cardio-facial (VCFS) syndromes. Hemizygosity of this region may also be the cause of over 100 different clinical signs. The CATCH 22 locus maps within a 1.5 Mb region, which encompasses several genes. However, no single defect in 22q11.2 hemizygous patients can be ascribed to any gene so far isolated from the critical region of deletion. We have identified a gene in the CATCH 22 critical region, whose functional features and tissue-specific expression suggest a distinct role in embryogenesis. This gene, UFD1L, encodes the human homolog of the yeast ubiquitin fusion degradation 1 protein (UFD1p), involved in the degradation of ubiquitin fusion proteins. Cloning and characterization of the murine homolog (Ufd1l) showed it to be expressed during embryogenesis in the eyes and in the inner ear primordia. These data suggest that the proteolytic pathway that recognizes ubiquitin fusion proteins for degradation is conserved in vertebrates and that the UFD1L gene hemizygosity is the cause of some of the CATCH 22-associated developmental defects.

Original languageEnglish
Pages (from-to)259-265
Number of pages7
JournalHuman Molecular Genetics
Volume6
Issue number2
DOIs
Publication statusPublished - Feb 1997

Fingerprint

Ubiquitination
Ubiquitin
Genes
Proteolysis
Embryonic Development
DiGeorge Syndrome
Hypocalcemia
Cleft Palate
Inner Ear
Vertebrates
Organism Cloning
Yeasts
Proteins

ASJC Scopus subject areas

  • Genetics

Cite this

UFD1L, a developmentally expressed ubiquitination gene, is deleted in CATCH 22 syndrome. / Pizzuti, Antonio; Novelli, Giuseppe; Ratti, Antonia; Amati, Francesca; Mari, Aldo; Calabrese, Giuseppe; Nicolis, Silvia; Silani, Vincenzo; Marino, Bruno; Scarlato, Guglielmo; Ottolenghi, Sergio; Dallapiccola, Bruno.

In: Human Molecular Genetics, Vol. 6, No. 2, 02.1997, p. 259-265.

Research output: Contribution to journalArticle

Pizzuti, A, Novelli, G, Ratti, A, Amati, F, Mari, A, Calabrese, G, Nicolis, S, Silani, V, Marino, B, Scarlato, G, Ottolenghi, S & Dallapiccola, B 1997, 'UFD1L, a developmentally expressed ubiquitination gene, is deleted in CATCH 22 syndrome', Human Molecular Genetics, vol. 6, no. 2, pp. 259-265. https://doi.org/10.1093/hmg/6.2.259
Pizzuti, Antonio ; Novelli, Giuseppe ; Ratti, Antonia ; Amati, Francesca ; Mari, Aldo ; Calabrese, Giuseppe ; Nicolis, Silvia ; Silani, Vincenzo ; Marino, Bruno ; Scarlato, Guglielmo ; Ottolenghi, Sergio ; Dallapiccola, Bruno. / UFD1L, a developmentally expressed ubiquitination gene, is deleted in CATCH 22 syndrome. In: Human Molecular Genetics. 1997 ; Vol. 6, No. 2. pp. 259-265.
@article{1469a396b7e64a3b83574d931f87cb9b,
title = "UFD1L, a developmentally expressed ubiquitination gene, is deleted in CATCH 22 syndrome",
abstract = "The CATCH 22 acronym outlines the main clinical features of 22q11.2 deletions (cardiac defects, abnormal facies, thymic hypoplasia; cleft palate and hypocalcemia), usually found in DiGeorge (DGS) and velo-cardio-facial (VCFS) syndromes. Hemizygosity of this region may also be the cause of over 100 different clinical signs. The CATCH 22 locus maps within a 1.5 Mb region, which encompasses several genes. However, no single defect in 22q11.2 hemizygous patients can be ascribed to any gene so far isolated from the critical region of deletion. We have identified a gene in the CATCH 22 critical region, whose functional features and tissue-specific expression suggest a distinct role in embryogenesis. This gene, UFD1L, encodes the human homolog of the yeast ubiquitin fusion degradation 1 protein (UFD1p), involved in the degradation of ubiquitin fusion proteins. Cloning and characterization of the murine homolog (Ufd1l) showed it to be expressed during embryogenesis in the eyes and in the inner ear primordia. These data suggest that the proteolytic pathway that recognizes ubiquitin fusion proteins for degradation is conserved in vertebrates and that the UFD1L gene hemizygosity is the cause of some of the CATCH 22-associated developmental defects.",
author = "Antonio Pizzuti and Giuseppe Novelli and Antonia Ratti and Francesca Amati and Aldo Mari and Giuseppe Calabrese and Silvia Nicolis and Vincenzo Silani and Bruno Marino and Guglielmo Scarlato and Sergio Ottolenghi and Bruno Dallapiccola",
year = "1997",
month = "2",
doi = "10.1093/hmg/6.2.259",
language = "English",
volume = "6",
pages = "259--265",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - UFD1L, a developmentally expressed ubiquitination gene, is deleted in CATCH 22 syndrome

AU - Pizzuti, Antonio

AU - Novelli, Giuseppe

AU - Ratti, Antonia

AU - Amati, Francesca

AU - Mari, Aldo

AU - Calabrese, Giuseppe

AU - Nicolis, Silvia

AU - Silani, Vincenzo

AU - Marino, Bruno

AU - Scarlato, Guglielmo

AU - Ottolenghi, Sergio

AU - Dallapiccola, Bruno

PY - 1997/2

Y1 - 1997/2

N2 - The CATCH 22 acronym outlines the main clinical features of 22q11.2 deletions (cardiac defects, abnormal facies, thymic hypoplasia; cleft palate and hypocalcemia), usually found in DiGeorge (DGS) and velo-cardio-facial (VCFS) syndromes. Hemizygosity of this region may also be the cause of over 100 different clinical signs. The CATCH 22 locus maps within a 1.5 Mb region, which encompasses several genes. However, no single defect in 22q11.2 hemizygous patients can be ascribed to any gene so far isolated from the critical region of deletion. We have identified a gene in the CATCH 22 critical region, whose functional features and tissue-specific expression suggest a distinct role in embryogenesis. This gene, UFD1L, encodes the human homolog of the yeast ubiquitin fusion degradation 1 protein (UFD1p), involved in the degradation of ubiquitin fusion proteins. Cloning and characterization of the murine homolog (Ufd1l) showed it to be expressed during embryogenesis in the eyes and in the inner ear primordia. These data suggest that the proteolytic pathway that recognizes ubiquitin fusion proteins for degradation is conserved in vertebrates and that the UFD1L gene hemizygosity is the cause of some of the CATCH 22-associated developmental defects.

AB - The CATCH 22 acronym outlines the main clinical features of 22q11.2 deletions (cardiac defects, abnormal facies, thymic hypoplasia; cleft palate and hypocalcemia), usually found in DiGeorge (DGS) and velo-cardio-facial (VCFS) syndromes. Hemizygosity of this region may also be the cause of over 100 different clinical signs. The CATCH 22 locus maps within a 1.5 Mb region, which encompasses several genes. However, no single defect in 22q11.2 hemizygous patients can be ascribed to any gene so far isolated from the critical region of deletion. We have identified a gene in the CATCH 22 critical region, whose functional features and tissue-specific expression suggest a distinct role in embryogenesis. This gene, UFD1L, encodes the human homolog of the yeast ubiquitin fusion degradation 1 protein (UFD1p), involved in the degradation of ubiquitin fusion proteins. Cloning and characterization of the murine homolog (Ufd1l) showed it to be expressed during embryogenesis in the eyes and in the inner ear primordia. These data suggest that the proteolytic pathway that recognizes ubiquitin fusion proteins for degradation is conserved in vertebrates and that the UFD1L gene hemizygosity is the cause of some of the CATCH 22-associated developmental defects.

UR - http://www.scopus.com/inward/record.url?scp=8044247810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8044247810&partnerID=8YFLogxK

U2 - 10.1093/hmg/6.2.259

DO - 10.1093/hmg/6.2.259

M3 - Article

VL - 6

SP - 259

EP - 265

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 2

ER -